This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Psychedelic therapy
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Psychedelic therapy refers to therapeutic practices involving the use of psychedelic drugs, particularly serotonergic psychedelics such as LSD, psilocybin, DMT, and 2C-B, primarily to assist psychotherapy. As an alternative to synonyms such as "hallucinogen", "entheogen", "psychotomimetic" and other functionally constructed names, the use of the term psychedelic ("mind-manifesting") emphasizes that those who use these drugs as part of a therapeutic practice believe these drugs can facilitate beneficial exploration of the psyche.
A small number of therapists continue to use MDMA in therapy despite its illegal status.[1]
List of substances researched in psychedelic therapy
External links
- List of investigational hallucinogens and entactogens (Wikipedia)
- Psychedelic therapy (Wikipedia)
- Legalizing Psychedelic Therapy (Indiegogo)
- MDMA-Assisted Psychotherapy (MAPS)
- Handbook For The Therapeutic Use Of Lysergic Acid Diethylamide-25 (MAPS)
- MDMA-Assisted Psychotherapy Treatment Manual (MAPS)
- Heffter.org
References
- ↑ Levy, Enno Freye ; in collaboration with Joseph V. (2009). Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs a comprehensive review on their mode of action, treatment of abuse and intoxication (Online-Ausg. ed.). Dordrecht: Springer Netherlands. p. 152. ISBN 9789048124480.
- ↑ Naranjo, C.; Shulgin, A. T.; Sargent, T. (1967). "Evaluation of 3, 4-methylenedioxeamphetamine (MDA) as an adjunct to psychotherapy". Pharmacology. 17 (4): 359–364. doi:10.1159/000137100.
- ↑ Yensen, R.; Di Leo, F. B.; Rhead, J. C.; Richards, W. A.; Soskin, R. A.; Turek, B.; Kurland, A. A. (1976). "MDA-assisted psychotherapy with neurotic outpatients: a pilot study". The Journal of Nervous and Mental Disease. 163 (4): 233–245. doi:10.1097/00005053-197610000-00002. PMID 972325.